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Abstract: This work reports the first electrochemical
immunoassay involving magnetic microbeads (MBs) for
the determination of galectin-3 (Gal-3), a β-galactosidase-
binding lectin that acts as mediator of heart failure (HF).
MBs-captured sandwich-type immune complexes and
amperometric detection at disposable screen-printed car-
bon electrodes were used. The immunoplatform showed a
detection limit of 8.3 pgmL  1, good reproducibility, and
excellent selectivity. The endogenous concentration of
Gal-3 in human plasma from HF patients was determined
with results in agreement with those obtained using
ELISA. The multiplexing feasibility of the developed
immunoplatform was demonstrated for the simultaneous
determination of Gal-3 and N-terminal pro-brain natriu-
retic peptide (NT-proBNP).
Keywords: Electrochemical immunoplatform · Magnetic beads · Galectin-3 · Plasma samples · Heart failure
1 Introduction
With the aging of population and increase of cardiovas-
cular health risk factors, the prevalence rate of heart
failure (HF) continues rising, becoming a serious chal-
lenge to the public health. Therefore, a rapid and accurate
diagnosis is essential to improve HF patients' outcomes.
However, HF is not easy to diagnose since clinical
symptoms are often non-specific [1]. HF diagnosis is
usually based on the combination of various parameters
such as patient‘s history, physical examination and
laboratory tests or imaging techniques, which require
well-trained operators and expensive equipment, some-
times not accessible in the majority of primary healthcare
facilities. Accordingly, objective evaluation within clin-
ically actionable times and preferably in a minimally
invasive manner using specific biomarkers may be one
avenue for routinely evaluation in order to diagnose HF,
assess the risk of future events, and guide efficient therapy
[2,3].
Brain natriuretic peptide (BNP) and N-terminal pro-
brain natriuretic peptide (NT-proBNP) are biomarkers of
great value in the diagnosis, prognosis evaluation and
clinical management of HF. However, they are influenced
by multiple factors such as age, renal function, or body-
mass index resulting in a large natural variation amongst
patients [1,4]. In consequence, seeking for complementary
biomarkers able to provide additional information to
improve risk stratification and to individualize therapy [5]
is highly desirable. In this context, several human clinical
studies have studied the role of the lectin galectin-3 (Gal-
3) in the development of HF [6]. Gal-3 is a 30 kDa
member of the carbohydrate-binding protein family of
lectins and plays an important regulatory role in cardiac
fibrosis and increased expression of collagens, which are
key factors in the development of heart hypertrophy and
progression of HF [7,8]. Interestingly, as Gal-3 is ex-
pressed before the development of overt clinical HF [9],
blood circulating levels of Gal-3 are proposed as prognos-
tic for acute HF in patients providing additive information
to natriuretic peptide levels [10]. It has been shown that
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activated macrophages release Gal-3, whose increased
levels are related to poor prognosis in HF [8], even
suggesting that serum Gal-3 is not only elevated in
patients with stable HF, but may also be predictive of
adverse outcomes in Acute HF Syndromes [10].
Several methods for Gal-3 determination have been
used. They include western blot and enzyme-linked
immunosorbent assays (ELISAs) [11–15], immunohisto-
chemistry [16–18], immunoassays [19,20], mass spectrom-
etry [21], flow cytometry [22], reverse transcription
polymerase chain reaction (RT-PCR) [23,24], surface
plasmon resonance [25,26], and the “routine Gal-3” assay
(Abbott Diagnostics) [20, 27]. Even though these methods
present high sensitivity and selectivity, they must be
improved since they are time-consuming and depend on
sophisticated, expensive, and centralized equipment, also
needing skilful operators. Therefore, sensitive, simple,
rapid, and low-cost methods for Gal-3 determination even
at decentralized settings are highly desirable.
In this context, electrochemical immunosensors have
attracted the attention of many scientists in recent years.
Their features such as high sensitivity, ease of operation
and low manufacturing cost, as well as the possibility of
simultaneous multi-target analysis, and miniaturization
make them very interesting devices for the analysis of
clinical biomarkers [28,29]. Among the wide number of
strategies used in the development of electrochemical
immunosensors, that involves magnetic microparticles
(MBs) shows unique and attractive physicochemical
properties that make them handy in a wide range of
applications [30]. Their integration into electrochemical
immunosensing devices enhances sensitivity through effi-
cient capturing and pre-concentration of the target
analyte and allows easy washing and isolation in the
presence of external magnetic fields thus aiding to remove
sample matrix effects [31]. So far, there is only one
electrochemical immunosensor reported for the determi-
nation of Gal-3, involving an integrated format [32].
Although this immunosensor exhibits an excellent sensi-
tivity (allowing detection of as little as 33.33 fgmL  1 Gal-3
in spiked serum samples) it requires time-consuming and
multi-step preparation of nanocomposites of N-doped
graphene nanoribbons immobilized Fe-based-Metal-or-
ganic frameworks deposited with Au nanoparticles (N-
GNRs  Fe-MOFs@AuNP) and of AuPt-Methylene blue
(AuPt  MB) as electrode modifiers and labels, and to
immobilize capture and detection antibody, respectively.
The immunoplatform required more than 12 h for its
preparation, apart from the 18 and 6 h, demanded by the
synthesis of N-GNRs  Fe-MOFs@AuNP and AuPt  MB,
respectively.
Hence, the purpose of this article is to report the first
electrochemical sandwich-type bioassay for the determi-
nation of Gal-3 based on the use of MBs and disposable
electrodes. Through the immobilization of the capture
antibody on HOOC  MBs and the modified MBs incuba-
tion in a mixture solution that contains the analyte and a
specific biotinylated detector antibody labelled with a
streptavidin-horseradish peroxidase (Strep-HRP) poly-
mer. The amperometric detection of the affinity reactions
was performed using disposable screen-printed carbon
electrodes (SPCEs) and the hydroquinone (HQ)/H2O2
system. The immunosensor achieves a good sensitivity
and selectivity and was successfully applied to the analysis
of Gal-3 in human plasma samples from patients followed
for HF. In addition, since there is limited specificity of
using a single cardiac biomarker to diagnose heart
problems and Gal-3 is thought to provide independent
and additive information to natriuretic peptides testing,
we also report the use of an electrochemical immunoplat-
form for the simultaneous determination of Gal-3 and
NT-proBNP.
2 Experimental
A description of apparatus, electrodes, reagents, and
solutions can be found in the Supporting Information.
2.1 Preparation of the MBs-based Sandwich
Immunocomplexes
2.1.1 MBs Bearing the Gal-3 Sandwich Immunocomplexes
A 3 μL-aliquot of the homogenized commercial
HOOC  MBs suspension was transferred into a 1.5-mL
micro-centrifuge tube and washed twice with 50 μL MES
buffer for 10 min (25 °C, 950 rpm). The MBs were then
magnetically separated by placing them in a magnetic
separator for 3 min in order to remove the supernatant
after all the involved steps. Thereafter, the activation of
the MBs surface carboxylic groups was carried out by
using 25 μL of a freshly prepared EDC/sulfo-NHS
solution for 35 min (25 °C, 950 rpm). After washing the
activated MBs twice with MES buffer, a 30 min incuba-
tion step (25 °C, 950 rpm) in 25 μL of a 10 μgmL  1 CAb
solution prepared in MES buffer was performed, washing
the CAb-MBs conjugates twice with MES buffer solution.
Subsequently, the residual activated groups were blocked
by incubating the modified CAb-MBs in a 1.0 M ethanol-
amine solution for 1 h (25 °C, 950 rpm). Finally, the CAb-
MBs were washed once with 0.1 M Tris-HCl buffer
(pH 7.2), twice with PBS, and stored at 4 °C in sterilized
PBS until their use.
The Gal-3 sandwich immunocomplexes were formed
by incubating the CAb-MBs in 25 μL of a mixture
solution that contained Gal-3 standard (or the sample to
analyze) and 0.5 μgmL  1 B-DAb for 30 min (25 °C,
950 rpm) prepared in casein blocking buffer solution.
After washing twice, the B-DAb-Gal-3-CAb-MBs were
incubated in a 1/5,000 diluted Strep-HRP solution (pre-
pared in casein blocking buffer) for 30 min (25 °C,
950 rpm). Finally, the sandwich-MBs immunocomplexes
were washed twice and re-suspended in 50 or 5 μL of
0.05 M phosphate buffer, pH 6.0, to carry out the single or
dual amperometric measurements, respectively.
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2.1.2 MBs Bearing the NT-proBNP Sandwich
Immunocomplexes
A similar protocol was followed for the preparation of
MBs bearing the NT-proBNP sandwich immunocom-
plexes. The activated HOOC-MBs were incubated for
30 min (25 °C, 950 rpm) with 25 μL of 25 μgmL  1 NT-
proBNP CAb made in MES buffer and washed twice with
50 μL of MES buffer. The CAbs-MBs were then incu-
bated for 60 min (25 °C, 950 rpm) in a 1.0 M ethanolamine
solution made in 0.1 M phosphate buffer, pH 8.0, followed
by one washing step with 50 μL of 0.1 M Tris-HCl buffer,
pH 7.2, and twice with 50 μL of 0.01 M PBS solution,
pH 7.5. The resulting MBs were stored at 4 °C in sterilized
PBS until their use.
The prepared CAb-MBs were subsequently incubated
in 25 μL of a mixture solution that contained NT-proBNP
standards (or the sample to be analyzed), 0.5 μgmL  1 B-
DAb and a 1/1,000 dilution Strep-HRP made in commer-
cial blocker casein solution for 30 min at 25 °C, 950 rpm.
Finally, the modified MBs were rinsed twice with 50 μL of
commercial blocker casein solution and kept in 5 μL of
0.05 M phosphate buffer, pH 6.0, to carry out the dual
amperometric measurements.
2.2 Amperometric Measurements
Once the whole suspension of MBs modified with the
sandwich immunocomplexes were drop casted on the WE
surface of the SPCE previously introduced in the appro-
priate magnet containing-PMMA casing, the SPE/casing
ensemble was connected to the potentiostat through the
specific cable connector and placed into an electrochem-
ical cell that contained 10 mL of 0.05 M phosphate buffer
solution (pH 6.0) and 1.0 mM fresh HQ. A detection
potential value of   0.2 V (vs the Ag pseudoreference
electrode) was selected for the single or dual amperomet-
ric measurements [33] upon addition of 50 μL of a 0.1 M
freshly prepared H2O2 solution. The recorded ampero-
metric signals were calculated as the difference between
the steady state and the background currents, being the
given values the mean value of three replicates. Error
bars were estimated as triple of the standard deviation of
each set of replicas (confidence intervals calculated for
α=0.05).
2.3 Analysis of Plasma Samples
The developed amperometric immunoassay was applied
to the analysis of human plasma samples provided by
Hospital Clinic of Barcelona from healthy individuals and
patients which are being followed for heart damage after
obtaining written informed consent from all of them. The
plasma samples, stored at   80 °C, were analyzed after a
10-times dilution with blocking buffer solution. The
endogenous concentrations of Gal-3 were determined by
using the standard additions method by spiking the
diluted plasma samples with increasing Gal-3 concentra-
tions (500–1,000 pgmL  1).
The results obtained with the immunoplatforms were
compared with those provided by the ELISA method
using the same immunoreagents and the protocol de-
scribed by Muñoz et al. [34], using the following reagent
concentrations: 50 μL of 4.0 μgmL  1 CAb solution (pre-
pared in PBS) 50 μL of Gal-3 standard solutions or
diluted plasma sample, (made in Reagent Diluent solu-
tion), 50 μL of 25 ngmL  1 B-DAb solution (in Reagent
Diluent solution) and 1/5,000 Strep-HRP-diluted in
Reagent Diluent solution. The determination of Gal-3 in
plasma samples was performed by interpolating the
optical density obtained for the 10-times diluted samples
into the calibration plot constructed with standards in the
250–2,000 pgmL  1 range.
3 Results and Discussion
3.1 Immunoplatform for the Determination of Gal-3
Figure 1 illustrates schematically the different steps
involved in the preparation and performance of the
immunosensor developed for the determination of Gal-3.
Covalent immobilization of CAb on the surface carboxylic
groups of MBs was performed through EDC/sulfo-NHS
chemistry. Once the remaining activated surface sites
were blocked with ethanolamine, the target Gal-3 was
sandwiched with a B-DAb further labeled with Strep-
HRP polymer. The MBs bearing the sandwich immuno-
conjugates were magnetically captured on the WE surface
of the SPCEs and the cathodic current variation was
recorded at   0.2 V vs the Ag pseudoreference electrode
using the H2O2/HQ system. This well-known and widely
used detection mechanism in amperometric biosensing
[35] involves the enzymatic reduction of H2O2 by HRP
and the regeneration of the oxidized HRP by HQ. The
oxidized form of the mediator, benzoquinone (BQ), is
reduced at the applied constant potential on the electrode
surface, providing a cathodic current proportional to the
concentration of the target protein in the sample.
3.1.1 Optimization of Working Variables
The influence of the experimental conditions on the
immunosensing amperometric signal was evaluated. The
tested working variables, the assessed ranges as well as
the chosen values, are listed in Table 1 and the results
shown in Figure 2. The optimal values were selected
according to the ratio obtained between the amperometric
signals measured at   0.2 V (vs. the Ag pseudoreference
electrode) for 0.0 (blank, B) and 1.0 ngmL  1 Gal-3
standard (signal, S) (signal-to-blank, S/B ratio).
Figures 2a and 2b show the effect of the CAb
concentration and incubation time, respectively. The S/B
ratio increased with the CAb concentration up to
10 μgmL  1 and levelled off for larger CAb concentrations,
probably due to the increase in the non-specific binding
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between the CAb and the B-DAb in the absence of Gal-
3. These results also show there was no discrimination for
the presence of Gal-3 when the MBs were not modified
with CAb, according to the rationale of the sandwich
immunoassay strategy depicted in Figure 1. Hence, a CAb
concentration of 10 μgmL  1 was chosen for further
experiments. Regarding the CAb incubation time, (Fig-
ure 2b) 30 min was enough for efficient CAb attachment
on the MBs.
Several working protocols involving a different num-
ber of 30-min incubation steps starting from the prepara-
tion of CAb-MBs were also tested (Figure 2c): 1) a single
incubation step in a mixture solution containing Gal-3, B-
DAb and Strep-HRP; 2a) two consecutive steps consisting
of the incubation in: i) a mixture solution containing Gal-
3 and B-DAb and ii) the Strep-HRP solution; 2b) two
sequential incubation steps in: i) a Gal-3 solution and ii) a
mixture solution containing B-DAb and Strep-HRP; and
3) three sequential steps in i) Gal-3, ii) B-DAb and iii)
Strep-HRP solutions. Figure 2c shows that the best S/B
ratio was obtained when the 2a) protocol was applied,
which can be attributed to the decrease in the nonspecific
binding between CAb and B-DAb when the B-DAb is at
the same time as the target protein in homogeneous
solution (see white 2a bar). This 2-step working protocol
(protocol 2a), of acceptable complexity and test time, was
selected for the immunoplatform development.
Figures 2d and 2e show as a better S/B ratio was
achieved for a B-DAb concentration in the Gal-3+B-
DAb mixture solution of 0.5 μgmL  1 and for an incuba-
tion time of 30 min. Larger B-DAb concentrations
provoked smaller S/B ratios due to a significant increase
in non-specific B-DAb adsorptions in the absence of Gal-
3 (Figure 2d). Moreover, larger incubation times of CAb-
MBs in the mixture solution than 30 min provided similar
S/B values since there was no significant difference
between the amperometric signals obtained in the absence
or in the presence of Gal-3 (Figure 2e).
Regarding the dilution and incubation time with the
Strep-HRP solution, higher S/B ratios were achieved
using a 1/5,000 dilution (Figure 2f) and a 30 min incuba-
tion time (Figure 2g). As it can be observed, a decrease in
the S/B ratio was obtained when higher concentrations or
incubation times were used as a result of the slight
increase and decrease in the amperometric responses
obtained in the absence and in the presence of Gal-3,
respectively.
Fig. 1. Schematic display of the preparation and functioning of the MBs-based immunoassay for the amperometric determination of
Gal-3.
Table 1. Experimental variables evaluated for the amperometric





CAb concentration, μg mL  1 0.0–50.0 10.0
Incubation time with CAb, min 0–60 30
Number of assay steps 1–3 2
B-DAb concentration, μg mL  1 0.25–2.5 0.5










www.electroanalysis.wiley-vch.de © 2020 The Authors. Published by Wiley-VCH GmbH Electroanalysis 2020, 32, 2775–2785 2778
Fig. 2. Assessment of the influence of the: concentration (a) and incubation time of CAb (b); number of incubation steps (c); B-DAb
concentration (d) and incubation time of CAb-MBs in the Gal-3+B-DAb mixture solution (e); concentration (f) and incubation time
of Strep-HRP loading (g), on the recorded amperometric signals in the absence (white bars) or in the presence (grey bars) of
1.0 ngmL  1 Gal-3 standards, and the obtained signal-to-blank ratios (S/B, blue triangles and lines). Error bars estimated as triple of the
standard deviation (n=3).
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3.1.2 Analytical Characteristics
The amperometric determination of Gal-3 was carried out
by constructing a calibration plot under the optimized
working conditions that fitted into the equation:   i (nA)
= (818�28) [Gal-3] (nAng  1mL)+ (186�50) (nA) (Fig-
ure 3). The linear range (r2=0.998) extended between
2.8×10  2 and 5 ngmL  1. A LOD of 8.3 pgmL  1 was
calculated following the 3× sb/m criterion, where sb was
estimated as the standard deviation for 10 measurements
recorded in the absence of Gal-3 and m is the slope of the
linear calibration plot. Interestingly, these analytical
features are suitable for the determination of Gal-3
considering its described range in clinical samples (1.4–
94.8 ngmL  1) [36,37]. It is worth remarking that reference
values of 18 ngmL  1 (males) and 20 ngmL  1 (females)
with values ranging between 5.0 and 24.4 ngmL  1 are
reported in serum of cardiac healthy individuals [20],
while reported values of Gal-3 in plasma samples range
between 14 and 20 ngmL  1 [5,38,39]. Moreover, different
studies have reported several cut-off values of Gal-3 of:
7.57 ngmL  1 in serum for predicting atrial fibrillation in
patients with acute myocardial infarction [40],
10.8 ngmL  1 in plasma to discriminate HF patients [7],
and 17.7 ngmL  1 in plasma to discriminate patients with
acute and chronic HF (CHF) [36].
Regarding the reproducibility of the developed meth-
od, a relative standard deviation (RSD) value of 7.7%,
was obtained by measuring the responses given by 8
different MBs-based immunoplatforms prepared in the
same manner (at a concentration level of 1.0 ngmL  1 of
Gal-3), which indicates the great reproducibility of the
developed methodology.
The long-term stability of prepared immunocaptors
(CAb-MBs) was checked by keeping them at 4 °C in
sterilized PBS (pH 7.5) solution. The control chart was
built by using the calculated mean value of 10 ampero-
metric measurements of a 1.0 ngmL  1 Gal-3 standard
solution on the first day of the study (the day the CAb-
MBs were prepared) as the central value, and �3×s of
this value as the upper and lower control limits,
respectively. Importantly, the amperometric signals ob-
tained with the stored magnetic bioconjugates continued
within the control limits for 60 days.
There are just few electrochemical biosensors for Gal-
3 determination reported in the literature. To the best of
our knowledge, there are only three papers for this
purpose [32, 41,42]. Two of them used Gal-3 ligand
probes, galactose-containing single-walled carbon nano-
tubes [42], achieving a LOD of 0.156 μgmL  1, and poly
(amido amine) (PAMAM) dendrimers used as scaffold
for lactose-ferrocene conjugates and gold nanoparticles
[41] with a LOD of 160 nM (~ 4.8 μgmL  1). Tang et al.
proposed a sandwich-type electrochemical immunosensor
for Gal-3 involving the use of a N-GNRs  Fe-MOF-
s@AuNPs-modified glassy carbon electrode (GCE) and
AuPt  MB nanocomposites as signal amplification probes,
reaching a LOD of 33.33 fgmL  1 [32]. This LOD is better
than the achieved in this work (8.3 pgmL  1). However,
our method does involve neither the use of time-
consuming multireagent/multistep processes for the prep-
aration of the nanomaterials and the electrode surface
modification nor the use of signal amplification tools.
Importantly, the achieved sensitivity is clearly sufficient to
tackle the determination in clinical samples where the
mean values for healthy individuals (~17 ngmL  1) are far
above. In addition, the analysis time is shorter (60 min vs
120 min). All these characteristics make the developed
immunosensor to meet better the requirements of bedside
Gal-3 determination.
Furthermore, the determination of Gal-3 using surface
plasmon resonance (SPR) based on lactose-modified gold
Fig. 3. Calibration curve obtained for the amperometric determination of Gal-3 standards a), and amperometric traces recorded b) by
using the developed magnetic immunoplatform. Error bars estimated as triple of the standard deviation (n=3).
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surfaces has also been studied [26]. Primo et al. [25]
reported a SPR method based on the use of an anti-Gal-3
antibody covalently attached to a 3-aminephenylboronic
monolayer built at a thiolated Au surface modified by
self-assembling of four bilayers of poly-(diallyldimeth-
ylammonium chloride) and graphene oxide. The claimed
LOD value was 2 ngmL  1, significantly higher than that
provided by the immunosensor reported in this work.
In addition, there are several commercial ELISA
methods available for Gal-3 determination claiming
LODs ranging between 50 and 600 pgmL  1, which are
clearly higher than the obtained in this work
(8.3 pgmL  1). Additionally, there are several automated
commercial methods such as BGM Galectin-3® test
(Abbott diagnostics), Vidas®Galectin-3 (bioMérieux) or
AR CHITEC Galectin-3® test (BG Medicine, Inc) that
measure Gal-3 in serum or plasma within 20 min to 3 h
30 min on microtiter plate platforms, reaching LOD
values ranging from 2.4 to 1.3 ngmL  1 [43]. Although the
sensitivity of all these methods is still adequate for Gal-3
determination, they require relatively expensive instru-
mentation, which is hardly portable and miniaturizing.
The competitive sensitivity along with the simplicity,
1 h-assay time (once prepared the CAb-MBs) and the
requirement of affordable and portable instrumentation,
make the proposed MBs-based amperometric immuno-
platform a proper tool, easy to automate and miniaturize,
to perform Gal-3 analysis even in the outpatient routine.
3.1.3 Selectivity
The selectivity of the antibodies employed in the develop-
ment of the immunosensor was assessed towards other
non-target proteins (human serum albumin, HSA, hemo-
globin, Hb, human immunoglobulin G, human IgG, N-
terminal-pro B type natriuretic peptide, NT-proBNP,
lipoprotein a, Lp(a), and soluble tyrosine kinase receptor,
sAXL) present in human serum by measuring the
amperometric responses for 0.0 and 1.0 ngmL  1 Gal-3
standards made in the absence and in the presence of the
non-target proteins at the concentration levels given in
the Figure 4 caption.
Figure 4 shows there were no apparent significant
differences among the obtained S/B ratios in the absence
and in the presence of the non-target proteins at the
assayed concentration. Regardless of the S/B ratio, the
amperometric signals for Gal-3 were slightly higher when
HSA, hemoglobin, Lp(a) and sAXL (bars 2, 3, 6 and 7,
respectively) were present in the solution, thus indicating
a sort of small interference from these non-target
proteins. Moreover, in the presence of hemoglobin a
slightly higher signal was obtained (Figure 4, white bars 3)
likely due to its intrinsic peroxidase activity [44, 45]. It is
worth mentioning also that the supplier of the used
immunoreagents for immunosensor development claimed
no potential cross-reactivity or interference towards
substances with similar molecular structures such as
recombinant human Gal-1, Gal-2, Gal-4 Gal-7, Gal-8 and
Gal-10 (all assayed at 50 ngmL  1). Noteworthy, the only
electrochemical immunosensor described for Gal-3 [32]
showed selectivity only against glucose, dopamine, L-
threonine and BSA.
3.1.4 Determination of Gal-3 in Plasma Samples from
Healthy Individuals and HF Patients
The developed MBs-based immunoplatform was em-
ployed to determine Gal-3 in six plasma samples collected
from healthy individuals and HF patients. The potential
occurrence of matrix effect was checked by building a
calibration plot using the 10-times diluted plasma samples
with commercial blocker casein solution and spiked with
increasing Gal-3 concentrations up to 1.0 ngmL  1. The
statistical comparison of the slope value of the calibration
plot constructed in plasma, (1,076�199) nAmLng  1 and
that prepared with buffered Gal-3 standard solutions,
(818�28) nAmLng  1, showed statistical differences
(texp=12.4> ttab=2.447), thus confirming the existence of
matrix effect in the diluted sample. Although dilutions
larger than 10 (of 1/25 and 1/50) were tested and, as
expected, gave rise to minimize the matrix effect, the
amperometric signals became small provoking an unac-
ceptable irreproducibility when they were interpolated
into the calibration plot constructed with Gal-3 standards.
Therefore, the Gal-3 endogenous concentration in human
plasma samples was determined by using the standard
additions method to the 10-times diluted samples.
The results obtained by triplicate with the immunosen-
sor for each plasma sample (Table 2) were compared with
those values obtained by using a conventional ELISA
methodology involving the use of the same immunore-
agents and following the protocol detailed in section 2.3.
The paired samples t-test showed that no significant
Fig. 4. Amperometric responses obtained for 0.0 (white bars) and
1.0 (grey bars) ngmL  1 Gal-3 standards (and the corresponding S/
B ratio, blue line and triangles) prepared without (1) or with
potentially interfering proteins: 0.05 mgmL  1 HSA (2),
0.25 mgmL  1 hemoglobin (3), 0.05 mgmL  1 human IgG (4),
0.25 ngmL  1 NT-proBNP (5), 1.5 μgmL  1 Lp(a) (6) and
3.5 ngmL  1 sAXL (7). Error bars estimated as triple of the
standard deviation (n=3).
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differences were apparent for the results provided by the
two methods (ttab=2.776; α=0.05), with a correlation plot
with slope and intercept values of (0.9�0.1) and (46�
150)×10  2 ngmL  1, respectively.
As it can be observed, the great reproducibility and
sensitivity of the developed sensor allow discriminating
between healthy and HF patients, for whom in all cases
Gal-3 levels higher than the lowest cut-off value set for
serum, 7.57 ngmL  1 [40], were obtained.
3.2 Multiplexing Feasibility of the Developed Platform:
Simultaneous Determination of Gal-3and NT-proBNP
As previously mentioned, it is well-accepted that the use
of a single biomarker is unlikely to be enough for a
comprehensive assessment of HF diagnosis [10]. Natriu-
retic peptides (BNP), and N-terminal pro-brain natriuretic
peptide (NT-proBNP), are well validated biomarkers in
HF and recommended by current guidelines for both
diagnosis and risk stratification of patients with chronic
HF [5,27,46,47]. Stretching of heart muscle cells, because
of cardiac volume overload, results in secretion of
proBNP, which is enzymatically cleaved into BNP and
NT-proBNP before being released into the bloodstream.
Although both biomarkers are at the same concentration
level, the circulation half-life of NT-proBNP in the body
is six times longer than BNP (120 vs 20 min, respectively),
making NT-proBNP a more suitable biomarker for HF
[48]. However, since they are influenced by age, renal
function and bodymass index, which leads to a large
natural variation amongst patients [1,4, 49], these natriu-
retic peptides have limited specificity when used individu-
ally to diagnose heart problems. In this regard, the use of
strategies that combine the multiple analysis of bio-
markers may be more informative and ultimately benefi-
cial in guiding HF therapy [50]. Moreover, apart from
biological processes involved in HF, Gal-3 has also
revealed a role in the development of other pathological
conditions such as tumorigenesis, autoimmune and in-
flammatory diseases [20, 27,51,52].
In this context, there is substantial interest in combin-
ing Gal-3 and NT-proBNP determination to provide
complementary prognostic information [5,49] and for
high-risk HF patient stratification [37]. Elevated levels of
Gal-3 are thought to provide independent and additive
information to natriuretic peptides testing [5, 10,53]. On
the other hand, Gal-3 is more stable over time, has a
smaller inter-individual variety, and has been shown to
provide less sensitivity but higher specificity than NT-
proBNP to predict CHF [9,27,54].
Several electrochemical immunosensors have been
implemented for the simultaneous detection of clinical
biomarkers which pair the sensitivity of electrochemistry
and the specificity of antibodies with robust designs [55–
58]. Nevertheless, as far as we know, there is no electro-
chemical immunoplatform described until now for the
simultaneous determination of Gal-3 and NT-proBNP.
Therefore, considering the good results obtained for Gal-
3, we report here a MBs-based dual immunoplatform for
the simultaneous amperometric determination of Gal-3
and NT-proBNP. The proposed platform involves the use
of sandwich-type electrochemical immunosensors with B-
DAbs further conjugated with Strep-HRP implemented
onto MBs and coupled to disposable dSPCEs, as depicted
in Figure 5a.
The possible cross-talk between the two adjacent
working electrodes of the dSPCE was evaluated under the
optimized conditions (see Table S1 in the supporting
Information). The results are displayed in Figure 5b. No
significant cross-talking was apparent due to the presence
of the non-target biomarkers: blue bars in experiments
(0;0) and (1;0), and orange bars in experiments (0;0) and
(1;0) were not significantly different. These results con-
firmed the feasibility of the dual immunoplatform for the
simultaneous determination of both cardiac biomarkers.
The calibration plots constructed under the optimal
experimental conditions for the simultaneous determina-
tion of Gal-3 and NT-proBNP standards are displayed in
Figure 5c. The linearity for Gal-3 ranges from 0.05 and
2.5 ngmL  1 (R2=0.996), fitting the equation i (nA)=
(507�46) [Gal-3] (nAmLng  1)+ (111�48) (nA). The
NT-proBNP calibration curve was linear over the 0.1–
2.0 ngmL  1 concentration range (R2=0.990) with the
equation i (nA)= (467�38) [NT-proBNP] (nAmLng  1)+
(37 �36) (nA). The LOD values (calculated according to
the 3× sb/m criterion as described in Section 3.1.2) were
15.8 and 35.6 pgmL  1 for Gal-3 and NT-proBNP, respec-
tively. The comparison of the amperometric responses
measured for six different dual immunoplatforms for
1.0 ngmL  1 Gal-3 and 1.0 ngmL  1 NT-proBNP standards
provided RSD values of 7.3 and 9.0%, respectively.
The obtained analytical characteristics are still below
the clinical range reported for Gal-3 in clinical samples
(1.4–94.8 ngmL  1) [36,37] and for NT-proBNP, whose
relevant concentration range depends on age (a cut-off
Table 2. Determination of Gal-3 (ng mL  1) in 10-times diluted human
plasma samples with the developed MBs-based amperometric immu-
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value of 450 pgmL  1 is established for people under the
age of 50, for 50–75 year old people the cut-off is
900 pgmL  1, and for people older than 75 years the cut-
off is 1,800 pgmL  1), considering that there is no risk of
HF at NT-proBNP concentrations lower than 300 pgmL  1
[59]. Although there are numerous methods described in
the literature for the individual determination of NT-
proBNP including ELISA and electrochemical biosensors
[60–64], to date no electrochemical platform has been
described for the simultaneous determination of NT-
proBNP and Gal-3 and only one commercial ELISA kit is
commercially available for the determination of these two
biomarkers (from LabCorp, Test 142005) which, apart
from requiring relatively expensive instrumentation (ELI-
SA plate readers), hardly portable and miniaturizable,
exhibits interference in serum samples collected from
people consuming a high dose of biotin.
4 Conclusions
This work describes the first electrochemical magneto-
immunoplatform developed to date for the determination
of Gal-3, a biomarker of remarkable interest to diagnose
and predict the progression of the cardiovascular risk.
The immunoplatform is based on the formation of
sandwich type immunocomplexes using biotinylated de-
tector antibodies enzymatically labeled with Strep-HRP
on MBs that are coupled to SPCEs to carry out
amperometric detection by using HQ/H2O2. The results
obtained demonstrate analytical characteristics compat-
ible with its practical applicability providing a LOD value
Fig. 5. Scheme and reactions involved in the MBs-based dual immunoplatform for the simultaneous determination of Gal-3 and NT-
proBNP (a); Amperometric measurements performed with the dual immunoplatform (WE1: Gal-3, orange bars and WE2: NT-
proBNP, blue bars) for standard mixtures containing: 0 ngmL  1 of both biomarkers; 1.0 ngmL  1 Gal-3 and 0 ngmL  1 NT-proBNP;
0 ngmL  1 Gal-3 and 1.0 ngmL  1 NT-proBNP; and 1.0 ngmL  1 Gal-3 and 1.0 ngmL  1 NT-proBNP (b); Calibration curves obtained for
the amperometric determination of Gal-3 (orange) and NT-proBNP (blue) standards (c). Error bars estimated as triple of the standard
deviation (n=3).
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1,000 times lower than the Gal-3 concentration in serum
or plasma samples from healthy individuals. The devel-
oped immunoplaform proves to be competitive with other
available methodologies mainly in terms of sensitivity and
possibility of performing the determination at the point of
care, compared to the only electrochemical immunosensor
described so far in terms of simplicity and time of
preparation and testing. Its potential for the determina-
tion of endogenous Gal-3 concentration in plasma
samples from HF patients after a simple 1/10 dilution has
been proved, providing results that agree with those
attained when the same immunoreagents are used in a
conventional ELISA methodology. Finally, it has also
been demonstrated the possibility of exploiting this
technology in the development of a dual immunosensor
platform that allows simultaneous determination of Gal-3
and NT-proBNP both to consolidate the role of Gal-3 as a
new biomarker for HF prognosis and to improve clinical
assessment and outcomes of HF patients.
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